Benitec Biopharma(BNTC)
$9.47+0.19 (+2.05%)
BNTC
Benitec Biopharma financials statements
$9.47
At close:+0.19 (+2.05%)
Want to see BNTC full AI Analyst Report?
Benitec Biopharma (BNTC) Ratios
319 Followers
Benitec Biopharma Ratios
BNTC's free cash flow for Q4 2026 was AU$-5.02M. For the 2026 fiscal year, BNTC's free cash flow was decreased by AU$-79.00K and operating cash flow was AU$-4.94M. See a summary of the company’s cash flow.
| Ratios | Jun 26 | Jun 25 | Jun 24 | Jun 23 | Jun 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 34.00 | 54.67 | 10.49 | 0.94 | 1.90 |
| Quick Ratio | 34.00 | 54.67 | 10.49 | 0.94 | 1.90 |
| Cash Ratio | 33.68 | 54.24 | 10.33 | 0.62 | 1.60 |
| Solvency Ratio | -8.03 | -16.33 | -4.31 | -4.50 | -5.76 |
| Operating Cash Flow Ratio | -3.09 | -13.09 | -3.94 | -4.53 | -6.28 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | AU$ 176.07M | AU$ 96.22M | AU$ 46.71M | AU$ -533.00K | AU$ 1.73M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.01 | 0.01 | 0.13 | 0.14 |
| Debt-to-Equity Ratio | 0.00 | 0.01 | 0.01 | 2.77 | 0.28 |
| Debt-to-Capital Ratio | 0.00 | 0.01 | 0.01 | 0.73 | 0.22 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.03 | 1.02 | 1.11 | 22.10 | 2.07 |
| Debt Service Coverage Ratio | 0.00 | 12.59 | 0.00 | -580.24 | -557.94 |
| Interest Coverage Ratio | 0.00 | 12.71 | 0.00 | -578.21 | -557.94 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.02 | -0.07 | 0.03 | 0.43 | 0.44 |
| Net Debt to EBITDA | 3.53 | 2.34 | 2.36 | 0.10 | 0.18 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | -408.00% | 87.67% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | -26038.67% | -24898.63% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | -25530.67% | -24457.53% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | -25441.33% | -24457.53% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | -26082.67% | -24942.47% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | -26082.67% | -24942.47% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | -26082.67% | -24942.47% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 88.97% | 90.79% | 96.25% | 102.52% | 101.98% |
| Return on Assets (ROA) | -24.94% | -38.07% | -41.66% | -438.22% | -304.84% |
| Return on Equity (ROE) | -25.73% | -38.97% | -46.04% | -9684.16% | -631.78% |
| Return on Capital Employed (ROCE) | -28.88% | -42.71% | -47.79% | -3926.13% | -518.86% |
| Return on Invested Capital (ROIC) | -28.80% | -42.55% | -47.50% | -2507.36% | -483.46% |
| Return on Tangible Assets | -24.94% | -38.07% | -41.66% | -438.22% | -304.84% |
| Earnings Yield | -7.31% | -8.95% | -29.20% | -347.68% | -48.02% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 1.36 | 24.33 |
| Payables Turnover | 0.53 | 1.97 | 0.25 | 0.33 | 0.02 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.12 | 0.07 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.02 | 0.01 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.07 | 0.01 |
| Cash Conversion Cycle | -692.82 | -185.27 | -1437.65 | -824.46 | -17099.44 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 267.67 | 15.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 692.82 | 185.27 | 1437.65 | 1092.13 | 17114.44 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 267.67 | 15.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.35 | -0.65 | -1.89 | -13.00 | -8.27 |
| Free Cash Flow Per Share | -0.36 | -0.65 | -1.91 | -13.00 | -8.28 |
| Dividend Paid and CapEx Coverage Ratio | -157.31 | -1310.44 | -108.40 | -18012.00 | -1223.00 |
| Capital Expenditure Coverage Ratio | -157.31 | -1310.44 | -108.40 | -18012.00 | -1223.00 |
| Operating Cash Flow Coverage Ratio | -21.68 | -27.78 | -68.32 | -32.22 | -19.60 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | -240.16 | -217.79 |
| Free Cash Flow Yield | -2.67% | -5.57% | -26.29% | -320.15% | -41.97% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -13.65 | -11.14 | -3.43 | -0.29 | -2.08 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 75.02 | 519.41 |
| Price-to-Book (P/B) Ratio | 3.52 | 4.35 | 1.58 | 27.85 | 13.16 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -37.48 | -17.95 | -3.80 | -0.31 | -2.38 |
| Price-to-Operating Cash Flow Ratio | -37.71 | -17.96 | -3.84 | -0.31 | -2.38 |
| Price-to-Earnings Growth (PEG) Ratio | 2.05 | 0.18 | 0.04 | 0.01 | 0.07 |
| Enterprise Value Multiple | -8.75 | -7.90 | -1.12 | -0.19 | -1.94 |
| Enterprise Value | 443.74M | 326.75M | 23.92M | 3.71M | 34.67M |
| EV to EBITDA | -8.75 | -7.90 | -1.12 | -0.19 | -1.94 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 49.45 | 474.87 |
| EV to Free Cash Flow | -26.69 | -13.84 | -1.22 | -0.21 | -2.18 |
| EV to Operating Cash Flow | -26.86 | -13.85 | -1.23 | -0.21 | -2.18 |
| Tangible Book Value Per Share | 3.80 | 2.69 | 4.60 | 0.15 | 1.50 |
| Shareholders’ Equity Per Share | 3.80 | 2.69 | 4.60 | 0.15 | 1.50 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.05 | 0.04 |
| Net Income Per Share | -0.98 | -1.05 | -2.12 | -14.12 | -9.47 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 0.89 | 0.91 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 170.32 | 154.41 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 91.04 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 6.03 | 11.92 |
| Income Quality | 0.36 | 0.62 | 0.89 | 0.92 | 0.87 |
Currency in AUD
